(Q39282309)

10 September 2017

Bipolar disorder associated with interferon-alpha treatment (English)

1 reference

10 September 2017

1 reference

Iancu I

1

1 reference

10 September 2017

Sverdlik A

series ordinal

2

1 reference

10 September 2017

Dannon PN

series ordinal

3

1 reference

10 September 2017

Lepkifker E

series ordinal

4

1 reference

10 September 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

Postgraduate Medical Journal

10 September 2017

1 reference

10 September 2017

73

1 reference

10 September 2017

834-835

1 reference

10 September 2017

866

1 reference

Clinical studies of recombinant interferon alfa-2a (Roferon-A) in cancer patients

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

The alpha interferons: clinical overview.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Chronic hepatitis C. Advances in diagnostic testing and therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Treatment of renal cell carcinoma with escalating doses of alpha-interferon

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Psychiatric complications of long-term interferon alfa therapy.

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Interferon enhances the excitability of cultured neurones

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Fluoxetine treatment of depression caused by interferon-alpha.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2431537

Suicide associated with alfa-interferon therapy for chronic viral hepatitis

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/9497963

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/PGMJ.73.866.834

1 reference

10 September 2017

1 reference

10 September 2017

1 reference